- Home
- ISPR vs TRML Comparison
ISPR vs TRML Comparison
Compare ISPR & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- TRML
- Stock Information
- Founded
- ISPR 2019
- TRML 2021
- Country
- ISPR United States
- TRML United States
- Employees
- ISPR N/A
- TRML N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- TRML Health Care
- Exchange
- ISPR Nasdaq
- TRML Nasdaq
- Market Cap
- ISPR 357.4M
- TRML 419.1M
- IPO Year
- ISPR 2023
- TRML N/A
- Fundamental
- Price
- ISPR $5.61
- TRML $19.87
- Analyst Decision
- ISPR Strong Buy
- TRML Strong Buy
- Analyst Count
- ISPR 1
- TRML 6
- Target Price
- ISPR $12.50
- TRML $54.00
- AVG Volume (30 Days)
- ISPR 66.8K
- TRML 181.0K
- Earning Date
- ISPR 11-11-2024
- TRML 11-07-2024
- Dividend Yield
- ISPR N/A
- TRML N/A
- EPS Growth
- ISPR N/A
- TRML N/A
- EPS
- ISPR N/A
- TRML N/A
- Revenue
- ISPR $148,382,357.00
- TRML N/A
- Revenue This Year
- ISPR $52.28
- TRML N/A
- Revenue Next Year
- ISPR $42.64
- TRML N/A
- P/E Ratio
- ISPR N/A
- TRML N/A
- Revenue Growth
- ISPR 12.82
- TRML N/A
- 52 Week Low
- ISPR $5.01
- TRML $12.12
- 52 Week High
- ISPR $13.87
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- ISPR 45.46
- TRML 31.96
- Support Level
- ISPR $5.47
- TRML $21.23
- Resistance Level
- ISPR $6.38
- TRML $22.80
- Average True Range (ATR)
- ISPR 0.26
- TRML 1.70
- MACD
- ISPR 0.01
- TRML -0.44
- Stochastic Oscillator
- ISPR 50.54
- TRML 3.42
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.